Article info
PDFCardiovascular medicine
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
- Correspondence to:
Dr Magnus Janzon, Department of Cardiology, Linköping Heart Centre, University Hospital, SE-581 85 Linköping, Sweden;
magnus.janzon{at}imv.liu.se
Citation
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
Publication history
- Accepted October 2, 2002
- First published March 1, 2003.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2003 by Heart